• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome.醛固酮拮抗剂可降低代谢综合征肥胖患者的血压并改善代谢参数。
J Clin Hypertens (Greenwich). 2010 Sep;12(9):753-5. doi: 10.1111/j.1751-7176.2010.00339.x. Epub 2010 Jul 8.
2
Spironolactone revisited.螺内酯再探讨。
J Clin Hypertens (Greenwich). 2011 Oct;13(10):783-4. doi: 10.1111/j.1751-7176.2011.00484.x. Epub 2011 Jul 18.
3
[Spironolactone reduces blood pressure and albuminuria of obese hypertensive patients with metabolic syndrome].[螺内酯可降低肥胖型高血压合并代谢综合征患者的血压及蛋白尿]
J Bras Nefrol. 2013 Jan-Mar;35(1):69-72. doi: 10.5935/01012800.20130011.
4
[Effect of combined treatment with dopamine receptor agonists and antagonists of aldosterone on the performance of daily blood pressure monitoring in patients with hypertension and concomitant obesity].[多巴胺受体激动剂与醛固酮拮抗剂联合治疗对高血压合并肥胖患者日常血压监测效果的影响]
Lik Sprava. 2012 Jan-Mar(1-2):63-8.
5
Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.螺内酯对少尿-无尿血液透析患者血压及肾素-血管紧张素-醛固酮系统的影响
Am J Kidney Dis. 2005 Jul;46(1):94-101. doi: 10.1053/j.ajkd.2005.03.005.
6
Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.螺内酯、依普利酮和新型醛固酮受体拮抗剂在内分泌性和原发性高血压中的应用。
J Hypertens. 2013 Jan;31(1):3-15. doi: 10.1097/HJH.0b013e3283599b6a.
7
Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.依普利酮：一种用于治疗高血压和心力衰竭的选择性醛固酮受体拮抗剂。
Heart Dis. 2003 Sep-Oct;5(5):354-63. doi: 10.1097/01.hdx.0000089783.30450.cb.
8
Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects.盐皮质激素受体拮抗剂对肥胖受试者胰岛素抵抗和内皮功能的影响。
Diabetes Obes Metab. 2014 Mar;16(3):268-72. doi: 10.1111/dom.12224. Epub 2013 Oct 31.
9
Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.直接肾素抑制剂治疗期间醛固酮逃逸对蛋白尿的影响及与盐皮质激素受体拮抗剂的联合效应。
Hypertens Res. 2013 Oct;36(10):879-84. doi: 10.1038/hr.2013.74. Epub 2013 Jul 18.
10
Eplerenone: cardiovascular protection.依普利酮：心血管保护作用。
Circulation. 2003 May 20;107(19):2512-8. doi: 10.1161/01.CIR.0000071081.35693.9A.

引用本文的文献

1
A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.盐皮质激素受体拮抗剂对葡萄糖稳态影响的系统评价与荟萃分析
Medicine (Baltimore). 2017 Dec;96(48):e8719. doi: 10.1097/MD.0000000000008719.
2
Pathophysiology and Potential Non-Pharmacologic Treatments of Obesity or Kidney Disease Associated Refractory Hypertension.肥胖或肾病相关性难治性高血压的病理生理学及潜在非药物治疗方法
Curr Hypertens Rep. 2017 Feb;19(2):18. doi: 10.1007/s11906-017-0713-6.
3
Spironolactone revisited.螺内酯再探讨。
J Clin Hypertens (Greenwich). 2011 Oct;13(10):783-4. doi: 10.1111/j.1751-7176.2011.00484.x. Epub 2011 Jul 18.

本文引用的文献

1
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.难治性高血压：诊断、评估与治疗。美国心脏协会高血压研究理事会专业教育委员会的科学声明。
Hypertension. 2008 Jun;51(6):1403-19. doi: 10.1161/HYPERTENSIONAHA.108.189141. Epub 2008 Apr 7.
2
Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration.
Hypertension. 2004 Jan;43(1):41-7. doi: 10.1161/01.HYP.0000105624.68174.00. Epub 2003 Nov 24.
3
Altered renal handling of sodium in human hypertension: short review of the evidence.人类高血压中肾脏对钠处理的改变：证据简述
Hypertension. 2003 May;41(5):1000-5. doi: 10.1161/01.HYP.0000066844.63035.3A. Epub 2003 Mar 31.
4
The kidney, hypertension, and obesity.肾脏、高血压与肥胖
Hypertension. 2003 Mar;41(3 Pt 2):625-33. doi: 10.1161/01.HYP.0000052314.95497.78. Epub 2003 Jan 20.
5
Angiotensin blockade prevents type 2 diabetes by formation of fat cells.血管紧张素阻断通过脂肪细胞的形成预防2型糖尿病。
Hypertension. 2002 Nov;40(5):609-11. doi: 10.1161/01.hyp.0000036448.44066.53.
6
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.醛固酮：心肌坏死和肾动脉病变的介质。
Endocrinology. 2000 Oct;141(10):3871-8. doi: 10.1210/endo.141.10.7711.
7
Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension.体重减轻和饮食中钠减少对高血压发病率的长期影响。
Hypertension. 2000 Feb;35(2):544-9. doi: 10.1161/01.hyp.35.2.544.
8
Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group.赖诺普利与氢氯噻嗪治疗肥胖高血压患者的多中心安慰剂对照试验。肥胖高血压患者治疗（TROPHY）研究组
Hypertension. 1997 Jul;30(1 Pt 1):140-5. doi: 10.1161/01.hyp.30.1.140.
9
Abnormal pressure natriuresis in the dog model of obesity-induced hypertension.肥胖诱导高血压犬模型中的压力性利钠异常。
Hypertension. 1994 Jan;23(1 Suppl):I8-11. doi: 10.1161/01.hyp.23.1_suppl.i8.
10
Incidence and precursors of hypertension in young adults: the Framingham Offspring Study.年轻成年人高血压的发病率及其先兆：弗雷明汉后代研究
Prev Med. 1987 Mar;16(2):235-51. doi: 10.1016/0091-7435(87)90087-9.

Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome.

作者信息

Costa Monica Barros, Andrade Ezequiel Danielle Guedes, Morais Lovis Julio Cesar, Oliveira Manoel Marques, Baumgratz de Paula Rogerio

出版信息

J Clin Hypertens (Greenwich). 2010 Sep;12(9):753-5. doi: 10.1111/j.1751-7176.2010.00339.x. Epub 2010 Jul 8.

DOI:10.1111/j.1751-7176.2010.00339.x
PMID:20883238
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8673323/
Abstract
摘要